Etrasimod, a once-daily oral selective sphingosine-1-phosphate receptor modulator, is well tolerated and effective in treating eosinophilic esophagitis (EoE), demonstrating sustained histologic ...

Offers In-Person and Virtual Access to Education, Support, and Community Eos Connection is more than a confere ...

Celldex (NASDAQ:CLDX) announced today new data demonstrating profound, sustained complete response and improved quality of life at 76 weeks, 7 months after the completion of dosing with barzolvolimab ...

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved ...

Feb. 3, 2025 — A multi-institutional study has identified one of the allergens responsible for eosinophilic esophagitis (EoE), an inflammatory disease of the esophagus. This is the first time ...

Sanofi presents positive results from DISCOVER phase 4 study of Dupixent in atopic dermatitis patients with skin of colour at 2025 RAD conference: Paris Tuesday, June 10, 2025, 16 ...

A groundbreaking study led by National Jewish Health researchers suggests that the skin may serve as a potential biomarker ...

The results provide physicians a potential new, noninvasive avenue to diagnose EoE by using skin tape. "This research provides the first evidence that skin barrier lipid abnormalities exist in EoE ...

Eosinophilic esophagitis (EoE) is a chronic disease that causes inflammation to your esophagus, the tube that connects your mouth and stomach. It’s related to chronic allergies to either food ...

The dynamics of the eosinophilic esophagitis market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as APT-1011 (Ellodi Pharmaceuticals ...

Eosinophilic esophagitis (EoE) is a chronic esophageal inflammatory disease of undetermined pathophysiology that results in dense mucosal eosinophilia and esophageal dysfunction. In childhood ...